| pubmed-article:15665929 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C0011860 | lld:lifeskim |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C0948089 | lld:lifeskim |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C0003015 | lld:lifeskim |
| pubmed-article:15665929 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15665929 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15665929 | pubmed:dateCreated | 2005-1-24 | lld:pubmed |
| pubmed-article:15665929 | pubmed:abstractText | Long-term oral treatment of patients with acute coronary syndromes and type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors is associated with positive, though ambiguous changes in the left-ventricular structure and function. These changes should be the reason for choosing optimal therapy ensuring better prognosis in this patient population. | lld:pubmed |
| pubmed-article:15665929 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15665929 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15665929 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15665929 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15665929 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15665929 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15665929 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15665929 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15665929 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:15665929 | pubmed:issn | 0007-4888 | lld:pubmed |
| pubmed-article:15665929 | pubmed:author | pubmed-author:IvanovaL ALA | lld:pubmed |
| pubmed-article:15665929 | pubmed:author | pubmed-author:Galenko-Yaros... | lld:pubmed |
| pubmed-article:15665929 | pubmed:author | pubmed-author:KanorskiiS... | lld:pubmed |
| pubmed-article:15665929 | pubmed:author | pubmed-author:RostovtsevaO... | lld:pubmed |
| pubmed-article:15665929 | pubmed:author | pubmed-author:Halil... | lld:pubmed |
| pubmed-article:15665929 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15665929 | pubmed:volume | 138 | lld:pubmed |
| pubmed-article:15665929 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15665929 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15665929 | pubmed:pagination | 301-4 | lld:pubmed |
| pubmed-article:15665929 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:meshHeading | pubmed-meshheading:15665929... | lld:pubmed |
| pubmed-article:15665929 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15665929 | pubmed:articleTitle | Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors: cardiohemodynamic effects and impact for prognosis. | lld:pubmed |
| pubmed-article:15665929 | pubmed:affiliation | Kuban State Medical Academy, Krasnodar. | lld:pubmed |
| pubmed-article:15665929 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15665929 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15665929 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
